Pediatric Neuroblastoma Treatment Market

Pediatric Neuroblastoma Treatment Market Study by Immunotherapy, Chemotherapy, and Others from 2023 to 2033

Analysis of Pediatric Neuroblastoma Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Table of Content

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Market

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Market Analysis and Forecast, 2023–2033

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter’s Five Force Analysis

5. Market Outlook

    5.1. Epidemiology Pediatric Neuroblastoma

    5.2. Pipeline Analysis

    5.3. Key Unmet Needs in the Market

    5.4. Global Market: Rate of Metastasis in Neuroblastoma

    5.5. Global Market: Neuroblastoma Relapse/Refractory cases

    5.6. Rate of Utilization of MIBG-131

6. Global Market Analysis and Forecast, by Therapy Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Therapy Type, 2023–2033

        6.3.1. Immunotherapy

        6.3.2. Chemotherapy

        6.3.3. Others

    6.4. Market Attractiveness, by Therapy Type

7. Global Market Analysis and Forecast, by End-user

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Distribution Channel, 2023–2033

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies & Drug Stores

    7.4. Market Attractiveness, by Distribution Channel

8. Global Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Rest of the World

    8.3. Market Attractiveness, by Region

9. North America Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Therapy Type, 2023–2033

        9.2.1. Immunotherapy

        9.2.2. Chemotherapy

        9.2.3. Others

    9.3. Market Value Forecast, by Distribution Channel, 2023–2033

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies & Drug Stores

    9.4. Market Value Forecast, by Country, 2023–2033

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis

        9.5.1. By Therapy Type

        9.5.2. By Distribution Channel

        9.5.3. By Country

10. Europe Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Therapy Type, 2023–2033

        10.2.1. Immunotherapy

        10.2.2. Chemotherapy

        10.2.3. Others

    10.3. Market Value Forecast, by Distribution Channel, 2023–2033

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies & Drug Stores

    10.4. Market Value Forecast, by Country/Sub-region, 2023–2033

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Rest of Europe

    10.5. Market Attractiveness Analysis

        10.5.1. By Therapy Type

        10.5.2. By Distribution Channel

        10.5.3. By Country/Sub-region

11. Rest of the World Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Therapy Type, 2023–2033

        11.2.1. Immunotherapy

        11.2.2. Chemotherapy

        11.2.3. Others

    11.3. Market Value Forecast, by Distribution Channel, 2023–2033

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies & Drug Stores

    11.4. Market Attractiveness Analysis

        11.4.1. By Therapy Type

        11.4.2. By Distribution Channel

12. Company Profiles

    12.1. United Therapeutics Corporation

        12.1.1. Company Overview (HQ, Business Segments, Employee Strength)

        12.1.2. Product Portfolio

        12.1.3. SWOT Analysis

        12.1.4. Financial Overview

        12.1.5. Strategic Overview

    12.2. APEIRON Biologics AG

        12.2.1. Company Overview (HQ, Business Segments, Employee Strength)

        12.2.2. Product Portfolio

        12.2.3. SWOT Analysis

        12.2.4. Financial Overview

        12.2.5. Strategic Overview

    12.3. Baxter

        12.3.1. Company Overview (HQ, Business Segments, Employee Strength)

        12.3.2. Product Portfolio

        12.3.3. SWOT Analysis

        12.3.4. Financial Overview

        12.3.5. Strategic Overview

    12.4. Cellectar Biosciences, Inc.

        12.4.1. Company Overview (HQ, Business Segments, Employee Strength)

        12.4.2. Product Portfolio

        12.4.3. SWOT Analysis

        12.4.4. Financial Overview

        12.4.5. Strategic Overview

    12.5. Pfizer, Inc.

        12.5.1. Company Overview (HQ, Business Segments, Employee Strength)

        12.5.2. Product Portfolio

        12.5.3. SWOT Analysis

        12.5.4. Financial Overview

        12.5.5. Strategic Overview

    12.6. MacroGenics, Inc.

        12.6.1. Company Overview (HQ, Business Segments, Employee Strength)

        12.6.2. Product Portfolio

        12.6.3. SWOT Analysis

        12.6.4. Financial Overview

        12.6.5. Strategic Overview

    12.7. Bayer AG

        12.7.1. Company Overview (HQ, Business Segments, Employee Strength)

        12.7.2. Product Portfolio

        12.7.3. SWOT Analysis

        12.7.4. Financial Overview

        12.7.5. Strategic Overview

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 01: List of acronyms used in the report

Table 02: Global Market: Pipeline Analysis

Table 03: Global Market: Pipeline Analysis

Table 04: Global Market: Pipeline Analysis

Table 05: Global Market: Pipeline Analysis

Table 06: Global Market: Pipeline Analysis

Table 07: Global Market: Pipeline Analysis

Table 08: Global Market: Pipeline Analysis

Table 09: Global Market: Pipeline Analysis

Table 10: Global Market: Pipeline Analysis

Table 11: Global Market: Pipeline Analysis

Table 12: Global Market: Pipeline Analysis

Table 13: Global Market: Pipeline Analysis

Table 14: Global Market: Pipeline Analysis

Table 15: Global Market Value (US$ Mn) Forecast, by Therapy Type, 2023–2033

Table 16: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 17: Global Market Value (US$ Mn) Forecast, by Region, 2023–2033

Table 18: North America Market Value (US$ Mn) Forecast, by Country, 2023–2033

Table 19: North America Market Value (US$ Mn) Forecast, by Therapy Type, 2023–2033

Table 20: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 21: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 22: Europe Market Value (US$ Mn) Forecast, by Therapy Type, 2023–2033

Table 23: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 24: Rest of the World Market Value (US$ Mn) Forecast, by Therapy Type, 2023–2033

Table 25: Rest of the World Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Figure 01: Global Market

Figure 02: Global Market Size (US$ Mn), by Therapy Type, 2022

Figure 03: Global Market Segments with Leading Market Share (%), 2022

Figure 04: Global Market Value (US$ Mn) Forecast, 2023–2033

Figure 05: Global Market Value Share (%), by Therapy Type, 2022

Figure 06: Global Market Value Share (%), by Distribution Channel, 2022

Figure 07: Global Market Value Share (%), by Region, 2022

Figure 08: Key Industry Events

Figure 09: Porter’s Five Forces Analysis

Figure 10: Epidemiology of Neuroblastoma

Figure 11: Epidemiology of Neuroblastoma: Numbers of Annual New Neuroblastoma Cases in Key Markets

Figure 12: Epidemiology of Neuroblastoma Key Research Findings

Figure 13: Epidemiology of Neuroblastoma, by Country

Figure 14: Epidemiology of Neuroblastoma, by Country

Figure 15: Epidemiology of Neuroblastoma, by Country

Figure 16: Key Unmet Needs in the Market

Figure 17: Global Market: Rate of Metastasis to the Brain

Figure 18: Global Market: Rate of Metastasis to the Brain

Figure 19: Global Market: Neuroblastoma Relapse/Refractory cases

Figure 20: Global Market: Neuroblastoma Relapse/Refractory cases

Figure 21: Global Market: Utilization of MIBG-131

Figure 22: Global Market: Utilization of MIBG-131

Figure 23: Global Market Value Share (%), by Therapy Type, 2023 and 2033

Figure 24: Global Market Attractiveness, by Therapy Type, 2023–2033

Figure 25: Global Market Revenue (US$ Mn) Forecast, by Immunotherapy, 2023–2033

Figure 26: Global Market Revenue (US$ Mn) Forecast, by Chemotherapy, 2023–2033

Figure 27: Global Market Revenue (US$ Mn) Forecast, by Others, 2023–2033

Figure 28: Global Market Value Share (%), by Distribution Channel, 2023 and 2033

Figure 29: Global Market Attractiveness, by Distribution Channel, 2023–2033

Figure 30: Global Market Revenue (US$ Mn) Forecast, by Hospital Pharmacies, 2023–2033

Figure 31: Global Market Revenue (US$ Mn) Forecast, by Retail Pharmacies &Drug Stores, 2023–2033

Figure 32: Global Market Value Share (%), by Region, 2023 and 2033

Figure 33: Global Market Attractiveness, by Region, 2023–2033

Figure 34: North America Market Revenue (US$ Mn) forecast, 2023–2033

Figure 35: North America Market Value Share (%), by Country, 2023 and 2033

Figure 36: North America Market Attractiveness, by Country, 2023–2033

Figure 37: North America Market Value Share (%), by Therapy Type, 2023 and 2033

Figure 38: North America Market Attractiveness, by Therapy Type, 2023–2033

Figure 39: North America Market Value Share (%), by Distribution Channel, 2023 and 2033

Figure 40: North America Market Attractiveness, by Distribution Channel, 2023–2033

Figure 41: Europe Market Revenue (US$ Mn) Forecast, 2023–2033

Figure 42: Europe Market Value Share (%), by Country/Sub-region, 2023 and 2033

Figure 43: Europe Market Attractiveness, by Country/Sub-region, 2023–2033

Figure 44: Europe Market Value Share (%), by Therapy Type, 2023 and 2033

Figure 45: Europe Market Attractiveness, by Therapy Type, 2023–2033

Figure 46: Europe Market Value Share (%), by Distribution Channel, 2023 and 2033

Figure 47: Europe Market Attractiveness, by Distribution Channel, 2023–2033

Figure 48: Rest of the World Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2023–2033

Figure 49: Rest of the World Market Value Share (%), by Therapy Type, 2023 and 2033

Figure 50: Rest of the World Market Attractiveness, by Therapy Type, 2023–2033

Figure 51: Rest of the World Market Value Share (%), by Distribution Channel, 2023 and 2033

Figure 52: Rest of the World Market Attractiveness, by Distribution Channel, 2023–2033

Figure 53: United Therapeutics Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 54: United Therapeutics Corporation Net sales of Unituxin (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 55: United Therapeutics Corporation Breakdown of Net Sales, by Product, 2022

Figure 56: United Therapeutics Corporation Research and Development Cost (US$ Mn), 2018–2022

Figure 57: United Therapeutics Corporation: SWOT Analysis

Figure 58: MacroGenics, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 59: MacroGenics, Inc. Net sales of Unituxin (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 60: MacroGenics, Inc. Net sales (US$ Mn) by key brands

Figure 61: MacroGenics, Inc. Research and Development Cost (US$ Mn), 2018–2022

Figure 62: MacroGenics, Inc.: SWOT Analysis

Figure 63: APEIRON Biologics AG: SWOT Analysis

Figure 64: Baxter Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2022

Figure 65: Baxter Breakdown of Net Sales (%), by Region, 2022

Figure 66: Baxter pipeline of generic products, 2018–2023

Figure 67: Baxter: SWOT Analysis

Figure 68: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 69: Pfizer Inc. R&D Expenses (US$ Mn), 2018–2022

Figure 70: Pfizer Inc.: SWOT Analysis

Figure 71: Cellectar Biosciences, Inc. Research and Development Cost (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 72: Cellectar Biosciences, Inc.: SWOT Analysis

Figure 73: Bayer Group Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 74: Bayer Group Breakdown of Net Sales (%), by Region, 2022

Figure 75: Bayer Group Breakdown of Net Sales (%), by Business Segment, 2022

Figure 76: Bayer Group: SWOT Analysis

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Pediatric Neuroblastoma Treatment Market

Schedule a Call